{"nctId":"NCT03534284","briefTitle":"Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis","startDateStruct":{"date":"2018-09-19","type":"ACTUAL"},"conditions":["Insomnia","End Stage Renal Disease"],"count":126,"armGroups":[{"label":"CBT-I","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Cognitive Behavioral Therapy for Insomnia"]},{"label":"Medication- Trazodone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Trazodone"]},{"label":"Medication- Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cognitive Behavioral Therapy for Insomnia","otherNames":["CBT-I"]},{"name":"Trazodone","otherNames":["Desyrel"]},{"name":"Placebo","otherNames":["Placebo (for trazodone)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Undergoing thrice-weekly maintenance hemodialysis for ≥ 3 months\n* Able to speak English\n* ISI score ≥ 10 at pre-screening with sleep disturbances for ≥ 3 nights per week for ≥ 3 months\n\nExclusion Criteria:\n\n* Severe cognitive impairment on Mini-COG cognitive test (score \\< 3)\n* Severe depression assessed by Patient Health Questionnaire (PHQ)-2 and if appropriate, PHQ-9\n* Suicidal Ideation\n* Alcohol abuse on CAGE alcohol assessment questionnaire (score ≥ 2) or substance abuse on Drug Abuse Screening Test (DAST)-10 questionnaire (score \\> 5)\n* Severe restless leg syndrome\n* Treatment with trazodone in the past one month\n* Known allergy to trazodone (self-report or by chart review)\n* Current treatment with monoamine oxidase inhibitors or in the preceding 14 days\n* Current treatment with linezolid (self-report or by chart review)\n* Current treatment with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (ziprasidone, chlorpromazine, thioridazine), and quinolone antibiotics\n* Pregnancy, or lactation, or women of childbearing potential not willing to use adequate birth control\n* Life Expectancy \\< 3 months\n* Expected to receive a kidney transplant or transition to home dialysis (peritoneal dialysis or home hemodialysis) within 6 months\n* Any other condition that, in the opinion of the investigator, should preclude patient participation in the clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Insomnia Severity Index (ISI) Short-term","description":"summary score obtained from the ISI, measuring insomnia, range from 0 to 28. Higher score indicates greater insomnia, at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.47","spread":null},{"groupId":"OG001","value":"11.97","spread":null},{"groupId":"OG002","value":"13.05","spread":null}]}]}]},{"type":"PRIMARY","title":"Insomnia Severity Index (ISI) Long-term","description":"summary score obtained from the ISI, measuring insomnia, range from 0 to 28. Higher score indicates greater insomnia, at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.34","spread":null},{"groupId":"OG001","value":"12.2","spread":null},{"groupId":"OG002","value":"11.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Pittsburgh Sleep Quality Index - Short-term","description":"Score from Pittsburgh Sleep Quality Index, measuring sleep quality, range 0 to 21. Higher scores indicates worse sleep quality: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.44","spread":null},{"groupId":"OG001","value":"11.09","spread":null},{"groupId":"OG002","value":"12.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Pittsburgh Sleep Quality Index - Long-term","description":"Score from Pittsburgh Sleep Quality Index, measuring sleep quality, range 0 to 21. Higher scores indicates worse sleep quality: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.15","spread":null},{"groupId":"OG001","value":"10.49","spread":null},{"groupId":"OG002","value":"9.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Epworth Sleepiness Scale - Short-term","description":"Score from Epworth Sleepiness Scale, measuring sleepiness, range 0 to 24. Higher scores indicates greater sleepiness: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.67","spread":null},{"groupId":"OG001","value":"8.46","spread":null},{"groupId":"OG002","value":"7.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Epworth Sleepiness Scale - Long-term","description":"Score from Epworth Sleepiness Scale, measuring sleepiness, range 0 to 24. Higher scores indicates greater sleepiness: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.27","spread":null},{"groupId":"OG001","value":"8.12","spread":null},{"groupId":"OG002","value":"7.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - FACIT Fatigue Scale- Short-term","description":"Score from FACIT Fatigue Scale, measuring fatigue, range 0 to 52. Higher scores indicates greater fatigue: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.55","spread":null},{"groupId":"OG001","value":"28.76","spread":null},{"groupId":"OG002","value":"28.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - FACIT Fatigue Scale- Long-term","description":"Score from FACIT Fatigue Scale, measuring fatigue, range 0 to 52. Higher scores indicates greater fatigue: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.65","spread":null},{"groupId":"OG001","value":"28.53","spread":null},{"groupId":"OG002","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Graded Chronic Pain Scale - Short-term","description":"Score from first item Graded Chronic Pain scale, measuring pain, range 0 to 10. Higher scores indicates greater pain: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":null},{"groupId":"OG001","value":"4.53","spread":null},{"groupId":"OG002","value":"4.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Graded Chronic Pain Scale - Long-term","description":"Score from first item Graded Chronic Pain scale, measuring pain, range 0 to 10. Higher scores indicates greater pain: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":null},{"groupId":"OG001","value":"4.32","spread":null},{"groupId":"OG002","value":"4.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Graded Chronic Pain Scale - Interference - Short-term","description":"Score from Second Item Graded Chronic Pain scale, measuring pain interference, range 0 to 10. Higher scores indicates greater interference from pain: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":null},{"groupId":"OG001","value":"4.07","spread":null},{"groupId":"OG002","value":"3.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Graded Chronic Pain Scale - Interference - Long-term","description":"Score from Second Item Graded Chronic Pain scale, measuring pain interference, range 0 to 10. Higher scores indicates greater interference from pain: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.88","spread":null},{"groupId":"OG001","value":"3.71","spread":null},{"groupId":"OG002","value":"4.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Patient Health Questionnaire 9 - Short-term","description":"Score from Patient Health Questionnaire 9, measuring depression, range 0 to 27. Higher scores indicates greater depression: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.98","spread":null},{"groupId":"OG001","value":"7.93","spread":null},{"groupId":"OG002","value":"8.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Patient Health Questionnaire 9 - Long-term","description":"Score from Patient Health Questionnaire 9, measuring depression, range 0 to 27. Higher scores indicates greater depression: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":null},{"groupId":"OG001","value":"8.04","spread":null},{"groupId":"OG002","value":"7.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Generalized Anxiety Disorder 7 Scale - Short-term","description":"Score from Generalized Anxiety Disorder 7 Scale, measuring anxiety, range 0 to 21. Higher scores indicates greater anxiety: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.18","spread":null},{"groupId":"OG001","value":"6.18","spread":null},{"groupId":"OG002","value":"7.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Generalized Anxiety Disorder 7 Scale - Long-term","description":"Score from Generalized Anxiety Disorder 7 Scale, measuring anxiety, range 0 to 21. Higher scores indicates greater anxiety: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.27","spread":null},{"groupId":"OG001","value":"6.35","spread":null},{"groupId":"OG002","value":"6.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 Scale - Physical Component Score - Short-term","description":"Score from Quality of Life Short Form 12 scale - Physical Component Score, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.87","spread":null},{"groupId":"OG001","value":"32.37","spread":null},{"groupId":"OG002","value":"32.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 Scale - Physical Component Score - Long-term","description":"Score from Quality of Life Short Form 12 scale - Physical Component Score, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.21","spread":null},{"groupId":"OG001","value":"32.07","spread":null},{"groupId":"OG002","value":"31.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 Scale - Mental Component Score - Short-term","description":"Score from Quality of Life Short Form 12 scale - Mental Component Score, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.53","spread":null},{"groupId":"OG001","value":"47.77","spread":null},{"groupId":"OG002","value":"48.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Outcomes (PRO) - Quality of Life Short Form 12 Scale - Mental Component Score - Long-term","description":"Score from Quality of Life Short Form 12 scale - Mental Component Score, measuring quality of life, range 0 to 100. Higher scores indicates better quality of life: at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.44","spread":null},{"groupId":"OG001","value":"49.23","spread":null},{"groupId":"OG002","value":"51.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Weekly Use of Sedatives/Hypnotics - Short-term","description":"This will be defined, as the number of days that the patient took a drug to help sleep, range from 0 to 7: at Week 7 describing the short-term effect of the intervention","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":null},{"groupId":"OG001","value":"1.29","spread":null},{"groupId":"OG002","value":"1.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Weekly Use of Sedatives/Hypnotics - Long-term","description":"This will be defined, as the number of days that the patient took a drug to help sleep, range from 0 to 7: at Week 25 describing the long-term effect of the intervention","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null},{"groupId":"OG001","value":"2.62","spread":null},{"groupId":"OG002","value":"2.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Measure of Sleep - Short-term","description":"Actigraphy measurement of average nighttime sleep efficiency (percent time asleep of time in bed): at Week 7 describing the short-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.03","spread":null},{"groupId":"OG001","value":"70.94","spread":null},{"groupId":"OG002","value":"70.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Measure of Sleep - Long-term","description":"Actigraphy measurement of average nighttime sleep efficiency (percent time asleep of time in bed): at Week 25 describing the long-term effect of the intervention","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.99","spread":null},{"groupId":"OG001","value":"71.6","spread":null},{"groupId":"OG002","value":"71.57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":43},"commonTop":["Hospitalization / Death","Hospitalization / Death","Hospitalization / Death","Hospitalization / Death","Hospitalization / Death"]}}}